» Articles » PMID: 18559533

Elevated CRAF As a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

Overview
Journal Cancer Res
Specialty Oncology
Date 2008 Jun 19
PMID 18559533
Citations 237
Authors
Affiliations
Soon will be listed here.
Abstract

Activating BRAF kinase mutations arise in approximately 7% of all human tumors, and preclinical studies have validated the RAF-mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase-ERK signaling cascade as a potentially important therapeutic target in this setting. Selective RAF kinase inhibitors are currently undergoing clinical development, and based on the experience with other kinase-targeted therapeutics, it is expected that clinical responses to these agents, if observed, will lead to the eventual emergence of drug resistance in most cases. Thus, it is important to establish molecular mechanisms underlying such resistance to develop effective therapeutic strategies to overcome or prevent drug resistance. To anticipate potential mechanisms of acquired resistance to RAF inhibitors during the course of treatment, we established drug-resistant clones from a human melanoma-derived cell line harboring the recurrent V600E activating BRAF mutation, which exhibits exquisite sensitivity to AZ628, a selective RAF kinase inhibitor. We determined that elevated CRAF protein levels account for the acquisition of resistance to AZ628 in these cells, associated with a switch from BRAF to CRAF dependency in tumor cells. We also found that elevated CRAF protein levels may similarly contribute to primary insensitivity to RAF inhibition in a subset of BRAF mutant tumor cells. Interestingly, AZ628-resistant cells demonstrating either primary drug insensitivity or acquired drug resistance exhibit exquisite sensitivity to the HSP90 inhibitor geldanamycin. Geldanamycin effectively promotes the degradation of CRAF, thereby revealing a potential therapeutic strategy to overcome resistance to RAF inhibition in a subset of BRAF mutant tumors.

Citing Articles

The paradoxical activity of BRAF inhibitors: potential use in wound healing.

Karhana S, Samim M, Nidhi , Khan M Arch Dermatol Res. 2025; 317(1):311.

PMID: 39873776 DOI: 10.1007/s00403-024-03785-5.


Transposon mediated functional genomic screening for BRAF inhibitor resistance reveals convergent Hippo and MAPK pathway activation events.

Chen L, Pruteanu-Malinici I, Dastur A, Yin X, Frederick D, Sadreyev R Sci Rep. 2025; 15(1):3048.

PMID: 39856157 PMC: 11760944. DOI: 10.1038/s41598-025-86694-5.


Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma.

He X, Deng H, Liu W, Hu L, Tan X Curr Treat Options Oncol. 2024; 25(12):1615-1633.

PMID: 39633237 DOI: 10.1007/s11864-024-01279-0.


BRAF-Mutated Melanoma Cell Lines Develop Distinct Molecular Signatures After Prolonged Exposure to AZ628 or Dabrafenib: Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells.

Zanre V, Bellinato F, Cardile A, Passarini C, Di Bella S, Menegazzi M Int J Mol Sci. 2024; 25(22).

PMID: 39596009 PMC: 11593403. DOI: 10.3390/ijms252211939.


Unveiling the Dynamic Interplay between Cancer Stem Cells and the Tumor Microenvironment in Melanoma: Implications for Novel Therapeutic Strategies.

Limonta P, Chiaramonte R, Casati L Cancers (Basel). 2024; 16(16).

PMID: 39199632 PMC: 11352669. DOI: 10.3390/cancers16162861.


References
1.
Daub H, Specht K, Ullrich A . Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov. 2004; 3(12):1001-10. DOI: 10.1038/nrd1579. View

2.
Solit D, Rosen N . Hsp90: a novel target for cancer therapy. Curr Top Med Chem. 2006; 6(11):1205-14. DOI: 10.2174/156802606777812068. View

3.
Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N . Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology. 2005; 128(2):270-9. DOI: 10.1053/j.gastro.2004.11.020. View

4.
Garnett M, Rana S, Paterson H, Barford D, Marais R . Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell. 2005; 20(6):963-9. DOI: 10.1016/j.molcel.2005.10.022. View

5.
Workman P, Burrows F, Neckers L, Rosen N . Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci. 2007; 1113:202-16. DOI: 10.1196/annals.1391.012. View